Physician profile
Herman Mathias
NPI 1487767265
$4,276.26
in general payments reported to CMS, 2019-2025
36 companies · $603 in 2025
The $603 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $844 · 2020: $570 · 2021: $356 · 2022: $474 · 2023: $381 · 2024: $1,048 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,033.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $623.18 | 2019-2025 | Repatha, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $381.20 | 2019-2024 | |
| Abbott Laboratories | $365.38 | 2023-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $258.50 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $231.61 | 2019-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $208.42 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $187.09 | 2019-2025 | Airsupra |
| Allergan, INC. | $182.45 | 2019-2020 | |
| Lilly USA, LLC | $179.35 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Corcept Therapeutics | $178.96 | 2019-2025 | Korlym |
| Lundbeck LLC | $160.26 | 2024-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $144.01 | 2019-2025 | Ingrezza |
| Astellas Pharma US INC | $136.46 | 2019-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.75 | 2021-2023 | Jardiance |
| Abbvie INC. | $87.33 | 2021-2023 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herman Mathias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.